[1]
Masaki, Y.; Shimizu, Y.; Yoshioka, T.; Feng, F.; Zhao, S.; Higashino, K.; Numata, Y.; Kuge, Y. Imaging mass spectrometry revealed the accumulation characteristics of the 2-nitroimidazole-based agent “Pimonidazole” in hypoxia. PLoS One, 2016, 11e0161639
[2]
Kourtzelis, I.; Rafail, S. The dual role of complement in cancer and its implication in anti-tumor therapy. Ann. Transl. Med., 2016, 4, 265.
[3]
Roviello, G.; Ravelli, A.; Polom, K.; Petrioli, R.; Marano, L.; Marrelli, D.; Roviello, F.; Generali, D. Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Lett., 2016, 372, 187-191.
[4]
Lokadasan, R.; James, F.V.; Narayanan, G.; Prabhakaran, P.K. Targeted agents in epithelial ovarian cancer: Review on emerging therapies and future developments. Ecanc. Med. Sci., 2016, 10, 626.
[5]
Yoo, S.Y.; Kwon, S.M. Angiogenesis and its therapeutic opportunities. Mediators Inflamm., 2013, 2013127170
[6]
Arjaans, M.; Schröder, C.P.; Oosting, S.F.; Dafni, U.; Kleibeuker, J.E.; de-Vries, E.G. VEGF pathway targeting agents; vessel normalization and tumor drug uptake: from bench to bedside. Oncotarget, 2016, 7, 21247-21258.
[7]
Tadakawa, M.; Takeda, T.; Li, B.; Tsuiji, K.; Yaegashi, N. The anti-diabetic drug metformin inhibits vascular endothelial growth factor expression via the mammalian target of rapamycin complex 1/hypoxia-inducible factor-1α signaling pathway in ELT-3 cells. Mol. Cell. Endocrinol., 2015, 399, 1-8.
[8]
Wang, L.H.; Jiang, X.R.; Yang, J.Y.; Bao, X.F.; Chen, J.L.; Liu, X.; Chen, G.L.; Wu, C.F. SYP-5, a novel HIF-1 inhibitor, suppressed tumor cell invasion and angiogenesis. Eur. J. Pharmacol., 2016, 791, 560-568.
[9]
Li, S.; Meng, W.; Guan, Z.; Guo, Y.; Han, X. The hypoxia-related signaling pathways of vasculogenic mimicry in tumor treatment. Biomed. Pharmacother., 2016, 80, 127-135.
[10]
Lee, S.O.; Kim, J.S.; Lee, M.S.; Lee, H.J. Anti-cancer effect of pristimerin by inhibition of HIF-1α involves the SPHK-1 pathway in hypoxic prostate cancer cells. BMC Cancer, 2016, 16, 701.
[11]
Du, J.; Xu, R.; Hu, Z.; Tian, Y.; Zhu, Y.; Gu, L.; Zhou, L. PI3K and ERK-induced Rac1 activation mediates hypoxia-induced HIF-1α expression in MCF-7 breast cancer cells. PLoS One, 2011, 6e25213
[12]
Mayer, I.A.; Arteaga, C.L. The PI3K/AKT pathway as a target for cancer treatment. Annu. Rev. Med., 2016, 67, 11-28.
[13]
Zhu, M.; Zhang, Q.; Wang, X.; Kang, L.; Yang, Y.; Liu, Y.; Yang, L.; Li, J.; Yang, L.; Liu, J.; Li, Y.; Zu, L.; Shen, Y.; Qi, Z. Metformin potentiates anti-tumor effect of resveratrol on pancreatic cancer by down-regulation of VEGF-B signaling pathway. Oncotarget, 2016, 7, 84190-84200.
[14]
Wang, D.; Wu, X. In vitro and in vivo targeting of bladder carcinoma with metformin in combination with cisplatin. Oncol. Lett., 2015, 10, 975-981.
[15]
Coyle, C.; Cafferty, F.H.; Vale, C.; Langley, R.E. Metformin as an adjuvant treatment for cancer: A systematic review and meta-analysis. Ann. Oncol., 2016, 27, 2184-2195.
[16]
Zhao, L.; Wen, Z.H.; Jia, C.H.; Li, M.; Luo, S.Q.; Bai, X.C. Metformin induces G1 cell cycle arrest and inhibits cell proliferation in nasopharyngeal carcinoma cells. Anat. Rec., 2011, 294, 1337-1343.
[17]
Ferletta, M.; Grawé, J.; Hellmén, E. Canine mammary tumors contain cancer stem-like cells and form spheroids with an embryonic stem cell signature. Int. J. Dev. Biol., 2011, 55, 791-799.
[18]
Borin, T.F.; Arbab, A.S.; Gelaleti, G.B.; Ferreira, L.C.; Moschetta, M.G.; Jardim-Perassi, B.V.; Iskander, A.S.; Varma, N.R.; Shankar, A.; Coimbra, V.B.; Fabri, V.A.; de-Oliveira, J.G.; Zuccari, D.A. Melatonin decreases breast cancer metastasis by modulating Rho-associated kinase protein-1 expression. J. Pineal Res., 2016, 1, 3-15.
[19]
Rattan, R.; Graham, R.P.; Maguire, J.L.; Giri, S.; Shridhar, V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia, 2011, 5, 483-491.
[20]
Chiavarina, B.; Whitaker-Menezes, D.; Martinez-Outschoorn, U.E.; Witkiewicz, A.K.; Birbe, R.; Howell, A.; Pestell, R.G.; Smith, J.; Daniel, R.; Sotgia, F.; Lisanti, M.P. Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth. Cancer Biol. Ther., 2011, 12, 1101-1113.
[21]
Jardim-Perassi, B.V.; Lourenço, M.R.; Doho, G.M.; Grígolo, I.H.; Gelaleti, G.B.; Ferreira, L.C.; Borin, T.F.; Moschetta, M.G.
Zuccari, P.C.D.A. Melatonin regulates angiogenic factors under hypoxia in breast cancer cell lines. Anticancer. Agents Med. Chem., 2016, 16, 347-358.
[22]
Moschetta, M.G.; Maschio, L.B.; Jardim-Perassi, B.V.; Gelaleti, G.B.; Lopes, J.R.; Leonel, C.; Gonçalves, N.; Ferreira, L.C.; Martins, G.R.; Borin, T.F.; Zuccari, D.A. Prognostic value of vascular endothelial growth factor and hypoxia-inducible factor 1α in canine malignant mammary tumors. Oncol. Rep., 2015, 5, 2345-2353.
[23]
Livak, K.J.; Schmittgen, T.D. Analyzing real-time PCR data by the comparative CT method. Nat. Protoc., 2008, 3, 1101-1108.
[24]
Hida, K.; Maishi, N.; Torii, C.; Hida, Y. Tumor angiogenesis--characteristics of tumor endothelial cells. Int. J. Clin. Oncol., 2016, 2, 206-212.
[25]
Karar, J.; Maity, A. PI3K/AKT/mTOR pathway in angiogenesis. Front. Mol. Neurosci., 2011, 4, 51.
[26]
Azim, S.; Zubair, H.; Srivastava, S.K.; Bhardwaj, A.; Zubair, A.; Ahmad, A.; Singh, S.; Khushman, M.; Singh, A.P. Deep sequencing and in silico analyses identify MYB-regulated gene networks and signaling pathways in pancreatic cancer. Sci. Rep., 2016, 6, 28446.
[27]
Phoenix, K.N.; Vumbaca, F.; Claffey, K.P. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ER alpha negative MDA-MB-435 breast cancer model. Breast Cancer Res. Treat., 2009, 113, 101-111.
[28]
Kato, H.; Sekine, Y.; Furuya, Y.; Miyazawa, Y.; Koike, H.; Suzuki, K. Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor. Biochem. Biophys. Res. Commun., 2015, 1, 115-121.
[29]
Ueno, S.; Kimura, T.; Yamaga, T.; Kawada, A.; Ochiai, T.; Endou, H.; Sakurai, H. Metformin enhances anti-tumor effect of L-type Amino Acid Transporter 1 (LAT1) inhibitor. J. Pharmacol. Sci., 2016, 2, 110-117.
[30]
Komeili-Movahhed, T.; Fouladdel, S.; Barzegar, E.; Atashpour, S.; Ghahremani, H.M.; Ostad, N.S.; Madjd, Z.; Azizi, E. PI3K/Akt inhibition and down-regulation of BCRP re-sensitize MCF7 breast cancer cell line to mitoxantrone chemotherapy. Iran. J. Basic Med. Sci., 2015, 5, 472-477.
[31]
Jiang, H.; Fan, D.; Zhou, G.; Li, X.; Deng, H. Phosphatidylinositol 3-kinase inhibitor (LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro and in vivo. J. Exp. Clin. Cancer Res., 2010, 29, 34.
[32]
Higashimura, Y.; Nakajima, Y.; Yamaji, R.; Harada, N.; Shibasaki, F.; Nakano, Y.; Inui, H. Up-regulation of glyceraldehyde-3-phosphate dehydrogenase gene expression by HIF-1 activity depending on sp1 in hypoxic breast cancer cells. Arch. Biochem. Biophys., 2011, 509, 1-8.
[33]
Dai, M.; Cui, P.; Yu, M.; Han, J.; Li, H.; Xiu, R. Melatonin modulates the expression of VEGF and HIF-1 alpha induced by CoCl2 in cultured cancer cells. J. Pineal Res., 2008, 44, 121-126.
[34]
Soraya, H.; Esfahanian, N.; Shakiba, Y.; Ghazi-Khansari, M.; Nikbin, B.; Hafezzadeh, H.; Dizaji, M.N.; Garjani, A. Anti-angiogenic effects of metformin, an AMPK activator, on human umbilical vein endothelial cells and on granulation tissue in rat. Iran. J. Basic Med. Sci., 2012, 15, 1202-1209.
[35]
Sahra, I.; Le, M.B.Y.; Tanti, J.F.; Bost, F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol. Cancer Ther., 2010, 5, 1092-1099.
[36]
Shafaee, A.; Dastyar, D.Z.; Islamian, J.P.; Hatamian, M. Inhibition of tumor energy pathways for targeted esophagus cancer therapy. Metabolism, 2015, 10, 1193-1198.
[37]
Aksoy, S.; Sendur, M.A.; Altundag, K. Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metformin. Med. Oncol., 2013, 2, 590.
[38]
Shank, J.J.; Yang, K.; Ghannam, J.; Cabrera, L.; Johnston, C.J.; Reynolds, R.K.; Buckanovich, R.J. Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol. Oncol., 2012, 2, 390-397.
[39]
Kabel, A.M.; Omar, M.S.; Balaha, M.F.; Borg, H.M. Effect of metformin and adriamycin on transplantable tumor model. Tissue Cell, 2015, 47, 498-505.
[40]
Liu, B.; Fan, Z.; Edgerton, S.M.; Deng, X.S.; Alimova, I.N.; Lind, S.E.; Thor, A.D. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle, 2009, 8, 2031-2040.
[41]
Viollet, B.; Guigas, B.; Sanz Garcia, N.; Leclerc, J.; Foretz, M.; Andreelli, F. Cellular and molecular mechanisms of metformin: An overview. Clin. Sci. (Lond.), 2012, 122, 253-270.
42
5